Laguna Bio Establishes First Italian Research Hub at Toscana Life Sciences

California-based biotechnology startup Laguna Bio has officially opened its first Italian research laboratory within the Toscana Life Sciences (TLS) bio-incubator in Siena. The company, which specializes in next-generation cancer immunotherapies, aims to leverage the facility’s specialized infrastructure to advance its proprietary QUAIL platform, a technology designed to transform pathogens into safe, targeted immune activators.

What is Laguna Bio’s objective in Siena?

Laguna Bio is focused on developing therapies that activate the human immune system to identify and destroy tumor cells. According to company CEO Jonathan Kotula, the Siena expansion is specifically designed to integrate expertise in bacterial pathogens with research on human immune cells. The company plans to use the TLS laboratory to refine its QUAIL platform, which seeks to make immunotherapy more scalable and effective for challenging conditions, including acute myeloid leukemia.

Why was Toscana Life Sciences selected?

The decision to locate in Siena stems from a need for highly specialized scientific capabilities. Kotula noted that the search for a partner began in 2024, leading to a collaboration with the TLS Laboratory of Molecular Immunology and Translational Oncology. Cristina Tinti, incubation manager at TLS, stated that the arrival of an international firm like Laguna Bio validates the competitiveness of the Tuscan research ecosystem. The TLS bio-incubator currently hosts nearly 50 companies and research groups, providing a shared environment for cross-disciplinary biotechnology development.

How does the QUAIL platform function?

The QUAIL platform represents a departure from traditional drug delivery by utilizing modified microbial components. By re-engineering these agents, the company aims to create therapies that can be administered in a controlled manner to trigger a T-cell response against cancer. This approach is intended to improve safety profiles compared to existing immunotherapies, which often struggle with off-target effects. Laguna Bio was co-founded by Kotula, Russell Carrington, and Daniel Portnoy, a professor at the University of California, Berkeley.

Future expansion and hiring

Laguna Bio currently operates with a core team in California managing legal, regulatory, and clinical operations. Following the establishment of the Siena site, the company has signaled intent to increase its headcount in Italy. Kotula confirmed that the firm plans to recruit new scientific personnel in the near term to support the ongoing research projects developed in partnership with TLS. This expansion marks a strategic shift for the startup as it transitions from early-stage development to more intensive translational research in the European market.

Key Takeaways

• Location: Laguna Bio has established its first Italian presence at the Toscana Life Sciences (TLS) bio-incubator in Siena.
• Technology: The company uses the QUAIL platform to turn pathogens into immune-activating cancer therapies.
• Partnership: The collaboration involves the TLS Laboratory of Molecular Immunology and Translational Oncology.
• Growth: The company plans to hire local researchers to scale its operations in Italy following the 2024 partnership launch.